Drug Profile
Pertuzumab/Trastuzumab - HER2 FISH pharmDx companion diagnostic - Dako
Alternative Names: erbb2 gene amplification kit; HER2 FISH pharmDx; Pertuzumab companion diagnostic - HER2 FISH pharmDx - Dako; Trastuzumab companion diagnostic - HER2 FISH pharmDx - Dako; Trastuzumab emtansine companion diagnostic - HER2 FISH pharmDx - DakoLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Dako A/S
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Gastric cancer
Most Recent Events
- 21 Jun 2012 Dako A/S has been acquired by Agilent Technologies
- 21 Oct 2010 Launched for Gastric cancer (Diagnosis) in USA (unspecified route)
- 21 Oct 2010 Registered for Gastric cancer (Diagnosis) in USA (unspecified route)